NUCHEM ALLOWED MOLECULES PATENT BY EUROPEAN PATENT OFFICE.Lorus Therapeutics Inc., Toronto, has announced that one of its subsidiaries, NuChem Pharmaceuticals Inc., through an exclusive license with Harvard University, has been allowed a patent by the European Patent Office. This patent protects the company's intellectual property interests with regard to certain molecules that inhibit cancer progression characterized by abnormal vascularization vascularization /vas·cu·lar·iza·tion/ (vas?ku-ler-i-za´shun) 1. the process of becoming vascular. 2. angiogenesis. 3. the surgically induced development of vessels in a tissue. . "The protection of our interests in these novel molecules in the European market is essential in a global industry such as ours," said Dr. Jim Wright, chief executive officer, Lorus. "This patent strengthens Lorus' growing intellectual patent portfolio, and complements the company's immunotherapy, antisense antisense, DNA or RNA manipulated in a laboratory so that its components (nucleotides) form a complementary copy of normal, or "sense," messenger RNA (mRNA; see nucleic acid). , tumor suppressor and U-Sense approaches for designing new anticancer drugs, all of which have recently received patent allowances in major markets." The patent, entitled "Use of Imidazole imidazole /im·id·az·ole/ (im?id-az´ol) 1. a heterocyclic organic compound in which two of five ring atoms are nitrogen; used as an insecticide. 2. any of a class of antifungal compounds containing this structure. for the Treatment of Diseases Characterized by Neovascularization," protects the use of specific small molecules in a class of compounds called imidazoles for the treatment of angiogenic conditions where neovascularization (new blood vessel formation) contributes to the progression of the disease by supplying nourishment to the diseased area. The molecules described in this patent inhibit the growth of cells responsible for neovascularization. The invention outlines solid tumors potentially treatable with the molecules described in the patent. For example, they include cancers of the brain, breast, cervix, colon, liver, lung, ovary ovary, ductless gland of the female in which the ova (female reproductive cells) are produced. In vertebrate animals the ovary also secretes the sex hormones estrogen and progesterone, which control the development of the sexual organs and the secondary sexual , pancreas, muscle, skin, testicles Testicles Also called testes or gonads, they are part of the male reproductive system, and are located beneath the penis in the scrotum. Mentioned in: Testicular Cancer, Testicular Surgery, Vasectomy , thyroid and kidney. About Lorus Lorus is a biopharmaceutical company focused on the research and development of cancer therapies. Lorus' goal is to capitalize on its research, pre-clinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination, to successfully manage cancer. Through its own discovery efforts and an active acquisition and in-licensing program, Lorus is building a portfolio of promising anti-cancer drugs. Late-stage clinical developments and marketing will be done in cooperation with strategic pharmaceutical partners. Founded in 1986, Lorus Therapeutics Inc. is a public company listed on the Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. under the symbol LOR, and on the OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). BB exchange under the symbol LORFF. For more information, visit http://www.lorusthera.com or call (416)798-1200, ext.380. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion